Overview

A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas

Status:
Recruiting

Trial end date:
2025-05-31

Target enrollment:

Participant gender:

Summary

This research study is studying a drug called pembrolizumab as a possible treatment for aggressive lymphoma or a histiocyte or dendritic cell neoplasm. The drug involved in this study is: -Pembrolizumab

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab